1-[(2-bromophenyl)methyl]-3-nitro-1H-pyrazole, 95.0%, 5g

(4-Oxo-4-phenyl-butyl)-carbamic acid tert-butylester, 98.0%, 1g

N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-sulfonamide, 98%, 1g

2-(Trifluoromethoxy)aniline>98.0%(GC)25g

GC-Kapillarsäule ROTI®Cap-1, unpolar, L 30 m, Ø-Innen 0,25 mm, Filmd. 0,50 µm, 1 Stück

5'-bromo-1',2'-dihydrospiro[cyclobutane-1,3'-pyrrolo[2,3-b]pyridine]-2'-one, 95.0%, 250mg

[3-(1-Methyl-1H-pyrazol-5-yl)phenyl]boronic acid, 95.0%, 1g

Methyl 2-Bromoisonicotinate>98.0%(GC)1g

2-Methoxy-4-(4-methylpiperidin-1-yl)aniline, 97.0%, 1g

2-(3,4-Dimethoxyphenyl)-5,7,8-trimethoxy-4H-chromen-4-one, 95.0%, 50mg

1,2-dinonyl benzene-1,2-dicarboxylate, 95.0%, 250mg

5-bromo-8-chloro-6-methyl-1,7-naphthyridine, 95.0%, 250mg

4,5-bis(trifluoromethyl)-1H-pyrazole, 97%, 1g